tobingj's  Instablog

Send Message
I am an individual investor. I dont mind risk as long as potential rewards are solid. I have built a diverse port folio which is down 10% after the recession. That is after taking various profits when available. I play long. I dont see the point in watching the day to day shareprice. Read the... More
  • Amarin Announces Positive Results Of Phase 1 Clinical Trial 1 comment
    Jun 21, 2013 9:22 AM | about stocks: AMRN


    Announcement today of results for study using Vascepa and Statin.

    In report also patent news.

    Amarin Announces Positive Results of Phase 1 Clinical Trial Measuring the Bioavailability of a Fixed-Dose Combination of Vascepa(NYSE:R) and a Statin Compared to Concomitant Administration

    BEDMINSTER, N.J., and DUBLIN, Ireland, June 21, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the results from a Phase 1 clinical trial that compared bioavailability of components from a fixed-dose combination of its flagship product, Vascepa® (icosapent ethyl), plus rosuvastatin, to concomitant administration of the two agents independently, and to rosuvastatin alone.

    "The encouraging results of this pharmacokinetic study represent a crucial step in the plan to solidify a fixed-dose formulation of Vascepa capsules with statins," stated Joseph Zakrzewski, Chairman and Chief Executive Officer of Amarin.

    In the multiple-dose study of 48 healthy volunteers, AMR-102 (the fixed-dose combination of icosapent ethyl and rosuvastatin, a leading statin) was assessed versus simultaneous administration of the individual agents, as well as versus rosuvastatin monotherapy, on pharmacokinetic measurements in order to show feasibility of the fixed-dose combination. The results proved promising, as there was no inhibition of either the rosuvastatin bioavailability, or of the bioavailability of the active metabolite EPA from Vascepa, observed with the fixed-dose combination product compared to the other arms of the trial.

    The AMR-102 test formulation was well tolerated. No serious adverse events were reported in the Phase 1 trial, nor was there an increase in reported side effects with either the fixed-dose combination, or the arm given co-administration of the two agents, versus those who received rosuvastatin alone.

    In the ANCHOR trial, Vascepa showed robust reductions in TGs and a broad range of other lipid parameters on top of optimized statin therapy, including atorvastatin, simvastatin, and rosuvastatin. Based on these encouraging efficacy results from ANCHOR, technical considerations, and market research, rosuvastatin was selected for this initial proof-of-principle pharmacokinetic study. The results of this Phase 1 study with rosuvastatin and Vascepa also bode well for the feasibility of applying this fixed-dose combination approach to a broader range of statins.

    Disclosure: I am long AMRN, GOOG.

    Stocks: AMRN
Back To tobingj's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • moeschempf
    , contributor
    Comments (30) | Send Message
    Thanks for the article. A lot of people are slowly waking up to the fact that Vascepa and the Vascepa/Statin combo franchise are going to be among the largest revenue generating drugs of all time.
    21 Jun 2013, 10:50 AM Reply Like
Full index of posts »
Latest Followers

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.